Pharma channel feed

Af­ter an odyssey of set­backs, FDA fi­nal­ly green-lights Newron’s Parkin­son’s drug Xada­go

9 years ago

What's on bio­phar­ma's auc­tion block? EY tracks a grow­ing ap­petite for pipeline di­vest­ment deals

9 years ago

Trump blasts Big Phar­ma again — “some­body’s get­ting very rich” — and promis­es drug price leg­is­la­tion

9 years ago

Es­pe­ri­on shares surge af­ter ex­ecs say the FDA in­di­cates its LDL pill could be ready to roll in 2019

9 years ago

CT­LA-4 bound for the clin­ic, Bris­tol-My­ers hands Cy­tomX $200M to kick off an ex­pand­ed dis­cov­ery pact

9 years ago

Ar­ray walks back its FDA pitch on binime­tinib, de­rail­ing plans for com­mer­cial launch

9 years ago

Heart at­tack while on Repatha? Am­gen will give you your mon­ey back

9 years ago
R&D

Cir­cas­sia forges a $300M COPD sales/de­vel­op­ment pact for US rights on two As­traZeneca drugs

9 years ago
R&D

As­traZeneca or­dered back in­to the penal­ty box on ZS-9 af­ter an­oth­er re­jec­tion on man­u­fac­tur­ing mal­func­tion

9 years ago

Af­ter be­ing spurned at the FDA, PTC buys a con­tro­ver­sial Duchenne MD ther­a­py from Marathon

9 years ago

Trump’s bud­get takes a big bite out of the NIH, with big new fees for bio­phar­ma

9 years ago
People
R&D

Seres dou­bles down on a mi­cro­bio­me do-over as the FDA clears a make-or-break study

9 years ago

Armed with CRISPR and a $38M round, eGe­n­e­sis tack­les the Holy Grail of xeno­trans­plan­ta­tion

9 years ago

Sanders, Cum­mings prob­ing FDA’s han­dling of Marathon af­ter a con­tro­ver­sial OK of old steroid for Duchenne MD

9 years ago

Im­munomedics lays out its case for an ac­cel­er­at­ed OK of IM­MU-132 in triple-neg­a­tive breast can­cer

9 years ago

FDA OKs Mer­ck’s Keytru­da for Hodgkin lym­phoma, a first in blood can­cer

9 years ago

Al­ler­gan antes up $90M in a land­mark CRISPR/Cas9 col­lab­o­ra­tion with Ed­i­tas on eye dis­eases

9 years ago
R&D

Watch out Pfiz­er, No­var­tis’ LEE011 bags quick OK for front­line use against breast can­cer

9 years ago

Roche and My­lan set­tle a scrap over Her­ceptin, clear­ing path to a glob­al launch of a knock­off drug

9 years ago

Cel­gene em­braces MTAP can­cer deal with fast-mov­ing col­lab­o­ra­tor Agios

9 years ago

With its lead an­tibi­ot­ic un­der a cloud, Cem­pra asks Mor­gan Stan­ley for help with a strate­gic re­view

9 years ago

FDA or­ders Karyopharm to halt en­roll­ment for all se­linex­or tri­als, cit­ing in­com­plete safe­ty warn­ing

9 years ago

Pres­i­dent Trump names Scott Got­tlieb as the next FDA com­mis­sion­er. What now?

9 years ago

Ar­gos Ther­a­peu­tics slash­es staff in the wake of the lat­est can­cer vac­cine flop

9 years ago
R&D
First page Previous page 330331332333334335336 Next page Last page
A service from the Financial Times